Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Program Tablets for Dogs
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation Round, biconvex tablets with four different colours and imprinted codes.
|
|
Red tablets contain: | 67.8 mg lufenuron CGV (side 1) FMF (side 2) |
Grey tablets contain: | 204.9 mg lufenuron CGV (side 1) GBG (side 2) |
White tablets contain: | 409.8 mg lufenuron CGV (side 1) DDD (side 2) |
For the prevention and lasting control of flea infestation and the treatment of flea allergic dermatitis in dogs. Program is effective against the dominant flea species Ctenocephalides felis and C. canis. Program tablets can be administered to all dogs including pregnant bitches and puppies taking solid food.
Dosage schedule for PROGRAM Tablets for Dogs | ||||
Dog weight |
| Red tablets (67.8 mg ai) | Grey tablets (204.9 mg ai) | White tablets (409.8 mg ai) |
|
|
|
|
|
2.3 kg to 6.7 kg |
| 1 tablet |
|
|
6.8 kg to 20 kg |
|
| 1 tablet |
|
21 kg to 40 kg |
|
|
| 1 tablet |
41 kg to 80 kg |
|
|
| 2 tablets |
Dosage
The minimum recommended dose rate is 10 mg/kg/month. When dosing puppies and growing dogs, the dose dispensed should be based on the animals expected weight at the end of the six month treatment period.
Recommended monthly dose
See table "Dosage schedule for PROGRAM Tablets for Dogs".
Administration
To be fully effective the tablets must be administered together with food, eg, added into a portion of the daily food, hidden in pieces of meat, etc or administered by mouth after feeding. After administration, the dog should be watched for several minutes to ensure that the whole dose has been swallowed.
To prevent flea infestations Program should be administered at monthly intervals for at least six months during the flea season, starting two months before fleas become active.
If the dog is already infested with fleas, no viable flea eggs are produced from 24 hours after the first administration. The speed of elimination of a pre-existing infestation is dependent upon the number of flea larvae and pupae in the environment when treatment starts and the climatic conditions.
If dogs have a high level of flea infestation at the start of the treatment, it may be necessary to administer a flea adulticide during the first one to two months. In cases of severe hypersensitivity further use of an adulticide may be needed.
It is essential that all dogs and all cats (except unweaned puppies and kittens) living in a household are treated with Program to stop flea reproduction.
For cats, use Program suspension.
Contra-indications, warnings, etc
Contra-indications
None. The product is compatible with other flea control products.
Warnings
Wash hands after use. Any unused product or waste material should be disposed of in accordance with national requirements.
Adverse reactions (frequency and seriousness)
On very rare occasions, nervous signs, itching, vomiting, or diarrhoea, have been reported in dogs following treatment with Program Tablets.
Keep out of the reach of children. For oral treatment only. For animal treatment only. Store in a dry place. Protect from light.
AVM-GSL (previously POM-V)
Blister packs of six tablets.
Program contains lufenuron, a benzoylurea derivative.
After administering Program orally to the dog, the active ingredient is quickly absorbed. Sufficient absorption is only achieved if administered on a full stomach. The low excretion rate assures an effective concentration of the active ingredient in the blood for one month.
Fleas take up the active ingredient through the blood and transfer it to their eggs. The formation of larval chitin structures, a process typical to insects, is blocked and the development of their numerous offspring is stopped. A new infestation of the home with fleas is prevented.
Fleas picked up by the dog outside the home environment are prevented from causing a new infestation of the home.
Marketing authorisation numbers
VM 12501/4013 PROGRAM* tablets 67.8 mg
VM 12501/4014 PROGRAM* tablets 204.9 mg
VM 12501/4015 Program tablets 409.8 mg